Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGc-043 in advanced EBV-positive solid tumors
NCT07028047Phase 1Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Vaccine mRNA, mRNA Vaccines, Cancer Vaccines
01
Overview
Phase 1, open-label trial of WGc-043 in solid tumor (5 arms), sponsored by Sun Yat-sen University. Primary endpoints: Dose limiting toxicity at 1 year, Treatment-related adverse events at 1 year and 1 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
WGc-043
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07028047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028047.